A Critical FDA Decision Looms for Aldeyra Therapeutics

The future of Aldeyra Therapeutics hinges on a single date: December 16, 2025. On that day, the U.S. Food and Drug Administration (FDA) will deliver a verdict on the New Drug Application for reproxalap, a treatment for dry eye disease. This regulatory milestone represents the most significant event in the company’s history, with the potential to fundamentally alter its trajectory.

Recent analyst activity reflects a growing sense of optimism. JonesTrading notably raised its price target to $9.00 this past Saturday, implying a substantial upside potential of nearly 67 percent. This revised outlook follows the FDA’s acceptance of the company’s resubmitted application for reproxalap, coupled with the assignment of a definitive Prescription Drug User Fee Act (PDUFA) action date. The establishment of this clear regulatory timeline provides investors with long-awaited clarity after previous clinical and regulatory setbacks.

Should investors sell immediately? Or is it worth buying Aldeyra Therapeutics?

Beyond its lead drug candidate, Aldeyra is advancing a second promising asset. The compound ADX-2191, developed for rare retinal disorders, has secured both Orphan Drug and Fast Track designations from the FDA as well as similar status from the European Medicines Agency (EMA). These designations are strategic advantages that can significantly expedite the development and review processes. The parallel progress in two distinct ophthalmic fields underscores the company’s focused strategy to capture value in the lucrative ophthalmology market.

The consensus among market analysts is a “Moderate Buy” recommendation, with an average price target of $9.50. Individual estimates, however, cluster in a tight range from $9.00 to $10.00, highlighting that the entire investment thesis is contingent on the December FDA decision. Approval for reproxalap would grant Aldeyra immediate access to a multi-billion-dollar market for ocular diseases. Conversely, a rejection could swiftly erase the equity gains accumulated in recent months, leaving shareholders facing considerable uncertainty. The months ahead will undoubtedly test the resolve of all stakeholders.